Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

298
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
298
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

236
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
236
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

10.8K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.8K
EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An integrated machine learning and computational framework with experimental validation for the identification of novel CXCR4 inhibitors.

European journal of medicinal chemistryยท2026
Same author

Enhanced Piezoelectric Effect in P(VDF-TrFE) through Synergistic Templating by PEDOT:PSS and Paper.

ACS applied electronic materialsยท2026
Same author

Genome wide comparative analysis of microsatellites in Bipolaris sorokiniana for diversity analysis and spot blotch disease diagnosis in wheat.

World journal of microbiology & biotechnologyยท2026
Same author

Graph-Based Classification with GNN-Explainer for Predicting Cardiac Toxicity Associated with Multi-Ion Channel Blockers.

Chemical research in toxicologyยท2026
Same author

Computational toxicology of <i>N</i>-nitrosamine impurities: from molecular structure to regulatory concern.

Toxicology mechanisms and methodsยท2026
Same author

Discovery of putative G-protein-biased ยต-opioid agonists via hierarchical virtual screening of ultra-large chemical space.

Molecular diversityยท2026

Related Experiment Video

Updated: Jun 7, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K

Predictive Modeling and Drug Repurposing for Type-II Diabetes.

Nitin Wankhade1, Anju Sharma1, Mushtaq Ahmad Wani1

  • 1Department of Pharmacoinformatics, National Institute of Pharmaceutical Education and Research, S. A. S. Nagar, Punjab 160 062, India.

ACS Medicinal Chemistry Letters
|November 20, 2024
PubMed
Summary

Researchers developed machine learning models to find new diabetes drugs targeting dipeptidyl peptidase-4 (DPP-4). A deep learning model identified promising drug candidates, offering hope for improved diabetes mellitus treatments.

More Related Videos

An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.6K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

526

Related Experiment Videos

Last Updated: Jun 7, 2025

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.6K
An In Ovo Model for Testing Insulin-mimetic Compounds
06:09

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

10.6K
Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model
06:22

Modeling and Evaluation of Murine Diabetic Cardiomyopathy Model

Published on: November 29, 2024

526

Area of Science:

  • Computational chemistry and cheminformatics
  • Pharmacology and drug discovery
  • Biotechnology and bioinformatics

Background:

  • Diabetes mellitus (DM) is a significant global health challenge.
  • Dipeptidyl peptidase-4 (DPP-4) is a crucial target for diabetes treatment.
  • Predictive modeling accelerates the identification of novel therapeutic agents.

Purpose of the Study:

  • To develop and validate machine learning models for predicting dipeptidyl peptidase-4 (DPP-4) inhibitors.
  • To identify novel DPP-4 inhibitors from a large chemical dataset and FDA-approved drugs.
  • To evaluate the potential of identified compounds as repurposed drugs for diabetes treatment.

Main Methods:

  • Utilized a curated dataset of 6,750 compounds for model training.
  • Employed machine learning (SVM, RF, NB) and deep learning (MTDNN) models.
  • Performed molecular docking and dynamic simulations for promising candidates.

Main Results:

  • The multitask deep neural network (MTDNN) model achieved high accuracy (98.62% train, 98.42% test) in predicting DPP-4 inhibitors.
  • MTDNN accurately predicted IC50 values with high correlation coefficients (0.979 train, 0.977 test).
  • Identified 100 potential DPP-4 inhibitors from FDA-approved drugs, with five showing significant potential after docking and dynamic analysis.

Conclusions:

  • The MTDNN model is a powerful tool for identifying novel DPP-4 inhibitors.
  • Five compounds demonstrate potential as repurposed drugs for diabetes treatment.
  • This study offers a promising avenue for developing new therapeutic strategies for diabetes mellitus.